Thalia Therapeutics CEO discusses early clinical progress with AML therapeutic miRisten
Published: 18:30 17 Nov 2026 AEDT
Thalia Therapeutics PLC (AIM:THAT) CEO Dr David Solomon talked with Proactive's Stephen Gunnion about encouraging interim Phase 1 results for miRisten, the company's experimental treatment for acute myeloid leukaemia (AML), an aggressive blood cancer.
The early data suggest the drug is well tolerated, with signs of reduced leukaemic activity and recovering white blood cell counts in some patients. Solomon explained how miRisten targets microRNA-126, which is elevated in AML and plays a role in the disease.
He stressed that the study remains at an early stage, with safety and tolerability the primary focus. However, the findings are providing grounds for further investigation of miRisten's potential, including in combination with existing treatments such as venetoclax.
The interview also explored the wider opportunity for RNA-based medicines in cancer and growing commercial interest in the field.
Working with its partners at City of Hope Medical Center in Los Angeles, Thalia expects to report topline Phase 1 results in early 2027. Solomon outlined the next steps towards a potential Phase 2 trial and the longer-term development pathway.
For more interviews with company executives and updates on the latest developments, visit Proactive’s YouTube channel. Give this video a like, subscribe to the channel and enable notifications so you never miss future content.
Read Proactive’s Editorial Policy here.
#ThaliaTherapeutics #miRisten #AML #ThaliaTherapeutics #miRisten #AML #AcuteMyeloidLeukaemia #CancerResearch #RNATherapeutics #MicroRNA #ClinicalTrials #Biotechnology #BiotechInvesting #DrugDevelopment #Oncology #Phase1Trial #ProactiveInvestors